Alphabet spinoff Isomorphic Labs reportedly raising funding at up to $50B valuation
Isomorphic Labs Ltd., an Alphabet Inc. spinoff working to accelerate drug discovery, is said to be raising a new funding round. The Bloomberg report that revealed the discussions today didn’t specify the size of the deal. The paper’s sources did, however, divulge that Isomorphic is eyeing a valuation of between $40 billion and $50 billion. […] The post Alphabet spinoff Isomorphic Labs reportedly…
Alphabet's spinoff, Isomorphic Labs, is reportedly in early-stage discussions to raise funding, with a potential valuation ranging from $40 billion to $50 billion, according to Bloomberg. The company focuses on accelerating drug discovery through its AI platform, IsoDDE, which automates labor-intensive research tasks. IsoDDE excels at identifying binding pockets - the specific points on a cell's surface where a drug attaches to neutralize disease-causing cells.
The platform is reportedly more than 50% more effective than competing tools and models protein-ligand complexes about twice as accurately as AlphaFold, Google DeepMind's chemistry-winning algorithm. Isomorphic's technology is primarily monetized through research partnerships with major drugmakers. In recent deals, the company secured nearly $3 billion in research agreements with Eli Lilly and Co., Novartis AG, and Johnson & Johnson, focusing on small molecule drugs.
Isomorphic's last funding round, a $2.1 billion round in March, included contributions from Alphabet, its venture capital funds, and external backers.
Written by urgent.news from SiliconANGLE's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
